1. At a Glance

What happens when Hyderabad’s quietest scientist decides to flex in the stock market? You get Sai Life Sciences Ltd (NSE: SAILIFE) — a lab coat with a ₹18,403 crore market cap swagger. The stock closed at ₹875 on Nov 7, 2025, barely down 5%, but don’t let that fool you — this company’s Q2FY26 numbers are loud enough to wake up even the sleepiest pharma analyst.
Revenue for Q2FY26 stood at ₹537 crore (up 36% YoY), while PAT jumped a jaw-dropping 102% YoY to ₹84 crore. The operating profit margin held a healthy 27%, and EPS clocked in at ₹4.00, annualized to ₹16. The company’s return on equity is now 11%, and ROCE stands at 14%.

And here’s the plot twist — 98% of revenue is export-driven, primarily from regulated markets like the US and Europe. When your clients are 17 out of the top 20 global pharma giants, even your Excel sheets smell like FDA approval.

So what’s cooking? Massive expansion, tax drama, a shiny new peptide research center, an IPO barely a year old, and profit that’s up 131% in a year. Sai Life’s quarterly results just proved that the “lab life” can also be a luxury life.

2. Introduction

Picture a Hyderabad lab in 1999 — a handful of scientists, some dusty pipettes, and a dream. Fast forward to 2025, and Sai Life Sciences Ltd (SLS) is playing in the big leagues of pharma outsourcing, with global biggies in its client list and a shiny ₹18,000+ crore market cap.

They don’t make tablets or capsules you’ll find in your local pharmacy; they make the molecules that make those tablets possible. SLS works across the drug discovery and development chain, offering services to innovator pharma and biotech companies — essentially, they’re the R&D nerds behind the billion-dollar blockbusters.

And business is booming. From ₹695 crore in FY19 to ₹2,053 crore TTM sales, this once-small research outfit has gone full-scale CRO-CDMO powerhouse. The Hyderabad-based company’s global expansion is no less dramatic than a Tollywood climax — new facilities in the US and Germany, peptide labs, and even veterinary API units.

Yet, despite all this science, SLS also has a little spice: an insider trading violation, a tax demand notice, and a CEO remuneration debate spicy enough to trend on LinkedIn finance bros’ feeds. But that’s the dual life of Sai Life — half scientist, half soap opera.

3. Business Model – WTF Do They Even Do?

If you’re still wondering what Sai Life actually does, here’s the short version: they make science profitable. The company is a full-service Contract Research, Development, and Manufacturing Organization (CRDMO). That means they help global pharma companies discover, design, develop, and manufacture new drugs — without having to build billion-dollar labs themselves.

They have two main divisions:

• Contract Research (CRO) – ~34% of revenue.
  Think chemistry and biology on steroids. Sai helps pharma clients with medicinal chemistry, biology, and pharmacokinetics, discovering potential molecules. Over 200 discovery programs and counting, with 40+ now in clinical phases.
• Contract Development & Manufacturing (CDMO) – ~66% of revenue.
  Once the molecule is discovered, Sai helps scale it — from grams in the lab to tons in the plant. 38 active APIs and intermediates across 28 commercial drugs, including seven blockbuster drugs.

With units in Hyderabad, Bidar, and Boston, this company’s global operations sound more like a biotech Netflix show than a typical Indian midcap. And with 98% of revenue coming from exports, Sai Life is basically a global CRO with an Indian heart — and possibly a German efficiency setting on its reactors.

4. Financials Overview

Annualized EPS: ₹16 → P/E ≈ 54.7x

Commentary:
That 102% YoY profit growth isn’t a typo — it’s a mic drop. Sai’s EBITDA margins stayed at a pharmaceutical-smooth 27%, even while adding new facilities. The quarterly revenue jump of 36% YoY is the best in the sector’s midcap class this quarter. The lab rats are running faster than the analysts’ calculators.

5. Valuation Discussion – Fair Value Range (Educational Only)

Let’s decode Sai Life’s ₹875 stock price through three boring-but-necessary methods:

a) P/E Method:
Annualized EPS = ₹16
Industry P/E = 32.8
Company P/E = 64.2
If valued at the sector median (≈33x), fair value = ₹16 × 33 = ₹528
At its current premium multiple (64x), fair value = ₹16 × 64 = ₹1,024

→ Fair Value Range: ₹520 – ₹1,020

b) EV/EBITDA Method:
EV/EBITDA = 31.1
EBITDA (TTM) = ₹544 Cr
EV = ₹18,292 Cr
Peer median (Sun Pharma, Dr. Reddy’s, Zydus) ≈ 18x
Fair value range = (18–32)×EBITDA ÷ shares
= ₹625 – ₹1,100

c) Simplified DCF (Educational Only):
Assume free cash flow growth 15% for 5 years, discount rate 10%.
Fair value range ≈ ₹750 – ₹1,000

Educational Disclaimer:
This fair value range is for educational purposes only. It’s not investment advice. It’s a calculator joke with numbers that actually came from the company’s filings.

6. What’s Cooking – News, Triggers, Drama

If you thought scientists lived boring lives, think again. Sai Life has been in the news more often than a celebrity marriage.

• September 2025: The company opened a 100,000 sq.ft CMC Process R&D Center in Hyderabad — doubling its peptide and oligonucleotide capacity. Peptides are the next gold rush in biotech, and Sai Life just bought a massive shovel.
• August 2025: Bidar facility upgrade completed — 700 KL total reactor capacity. That’s not just chemistry; that’s chemistry with attitude.
• September 2025 AGM: Reappointed MD/CEO Krishnam Raju Kanumuri. His PLI (performance-linked incentive) is tied